Regeneron Pharmaceuticals is a biotechnology company that discovers, develops and manufactures medicines for serious diseases, using genetics, genomics and data-powered research.
Regeneron Pharmaceuticals, Inc is a biotechnology company founded in 1988 that invents, develops and commercializes medicines for serious diseases. Data-intensive work sits at the centre of its research operation: the Regeneron Genetics Center (RGC) applies large-scale genetics and genomics analysis to generate data-powered insights, and the company cites data-powered insights among its core technical domains alongside antibody discovery, bispecific antibodies and genetic medicine platforms.
The company's proprietary VelociSuite technologies produce optimised fully human antibodies and new classes of bispecific antibodies. Nearly all of Regeneron's approved treatments and product candidates were discovered in its own laboratories. Its therapeutic areas include ophthalmology, allergy and inflammation, oncology, cardiovascular and metabolic disease, neurology, hematology, infectious diseases and rare diseases, and it maintains a global network of research teams.
Regeneron employs more than 15,000 people, among them over 1,400 holding MDs and/or PhDs, and has operated for more than 35 years. It was founded and is led by physician-scientists. Beyond discovery, the company performs biologics manufacturing and drug development in-house.
